Step 1 topics → Endocrine → Carcinoid Tumor and Carcinoid Syndrome

Carcinoid Tumor and Carcinoid Syndrome

USMLE Step 1 trap: Misses that tryptophan diversion—not serotonin excess per se—causes niacin deficiency in carcinoid syndrome. Carcinoid tumors divert tryptophan toward serotonin production, depleting the substrate for niacin synthesis and causing niacin deficiency (pellagra: diarrhea, dermatitis, dementia).

Carcinoid tumors are neuroendocrine tumors arising most commonly in the GI tract and lung, and USMLE Step 1 hammers the distinction between having a carcinoid tumor and having carcinoid syndrome — students consistently forget that syndrome requires hepatic metastases or a non-portal primary because the liver normally destroys serotonin on first pass. They also miss that carcinoid tumors cause pellagra by shunting tryptophan away from niacin synthesis — excess serotonin isn't the explanation, substrate competition is. Carcinoid syndrome (flushing, diarrhea, wheezing, right-sided valvular lesions) only develops when vasoactive substances bypass hepatic clearance.

The exam tests this from multiple angles: clinical presentation vignettes that include the niacin-deficiency angle (pellagra symptoms in a patient with carcinoid), lab-based questions about which test to order and why, and management questions about octreotide. The trickiest conceptual layer is the tryptophan-to-niacin pathway — students know serotonin is overproduced but miss that tryptophan is the shared precursor, so carcinoid tumors starve niacin synthesis by hoarding substrate. The pellagra symptoms (diarrhea, dermatitis, dementia) can therefore appear in the vignette alongside classic carcinoid features.

On USMLE Step 1, students also conflate the two main diagnostic tests: urine 5-HIAA and serum chromogranin A. These are not interchangeable. Understanding what each test actually measures — and when each is more appropriate — is exactly the kind of mechanistic distinction the exam rewards. Similarly, octreotide is frequently misunderstood as a serotonin blocker when it is actually a somatostatin analog that suppresses secretion at the tumor level.

From real student decks
46%have cards covering this topic
16%have mature cards

Common misconceptions

Common mistake
Wrong: Carcinoid syndrome causes pellagra-like symptoms only because serotonin is overproduced, not because tryptophan is diverted away from niacin synthesis.
Right: Carcinoid tumors divert tryptophan toward serotonin production, depleting the substrate for niacin synthesis and causing niacin deficiency (pellagra: diarrhea, dermatitis, dementia).
Serotonin overproduction itself does not cause pellagra — the problem is upstream. Carcinoid tumors shunt tryptophan away from the normal niacin biosynthesis pathway to make more serotonin, depleting the precursor niacin needs. The result is niacin deficiency regardless of serotonin levels, which is why a carcinoid patient can present with the pellagra triad (diarrhea, dermatitis, dementia) on top of classic carcinoid symptoms. Think of it as a substrate competition problem, not a serotonin-toxicity problem.
Common mistake
Wrong: Carcinoid syndrome can occur with any carcinoid tumor regardless of location.
Right: Carcinoid syndrome typically requires hepatic metastases (or a primary outside portal drainage) so that vasoactive substances bypass first-pass hepatic metabolism and reach the systemic circulation.
A carcinoid tumor can exist for years without causing carcinoid syndrome because the liver efficiently metabolizes serotonin and other vasoactive peptides during first-pass metabolism. Syndrome develops only when that filter is bypassed — either because the tumor has metastasized to the liver (overwhelming hepatic clearance) or because the primary tumor drains directly into the systemic circulation rather than the portal system (e.g., bronchial or ovarian primaries). Finding carcinoid syndrome in a patient without hepatic metastases should prompt you to look for a non-GI primary.
Common mistake
Wrong: 5-HIAA and chromogranin A are interchangeable tests for carcinoid diagnosis.
Right: Urine 5-HIAA reflects serotonin metabolite excretion and is specific for functional carcinoid syndrome, while chromogranin A is a broader neuroendocrine tumor marker useful even in non-serotonin-secreting tumors.
Urine 5-HIAA measures the serotonin breakdown product excreted in urine, making it specific for functional serotonin-secreting tumors — it confirms that the tumor is actually producing and releasing serotonin. Chromogranin A is a protein co-released from neurosecretory granules across all neuroendocrine tumors, whether or not they secrete serotonin, making it a sensitive but less specific marker. Use 5-HIAA to confirm carcinoid syndrome; use chromogranin A when you need a broader neuroendocrine tumor marker or when the tumor may not be serotonin-secreting.
Common mistake
Wrong: Octreotide treats carcinoid syndrome by blocking serotonin receptors.
Right: Octreotide is a somatostatin analog that binds somatostatin receptors on tumor cells, inhibiting the secretion of serotonin and other vasoactive peptides.
Octreotide does not block serotonin receptors — it never touches downstream serotonin signaling. It is a synthetic analog of somatostatin that binds somatostatin receptors expressed on the surface of carcinoid tumor cells, and this binding inhibits the tumor's secretory machinery, reducing release of serotonin, histamine, and other vasoactive peptides. The result is symptom control at the source, not receptor-level blockade. This mechanism also explains why somatostatin receptor imaging (OctreoScan) works for localization — the same receptors that octreotide binds are the ones the tracer targets.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Recognize the full carcinoid syndrome presentation — flushing, secretory diarrhea, bronchospasm, right-sided heart valve lesions — and understand why tryptophan diversion toward serotonin causes pellagra (niacin deficiency) with its own triad of diarrhea, dermatitis, and dementia.
  2. Know which diagnostic tests to order and why: urine 5-HIAA is the specific functional marker for serotonin-secreting tumors, chromogranin A is a general neuroendocrine marker useful even when tumors are non-serotonin-secreting, and somatostatin receptor scintigraphy (OctreoScan) localizes disease.
  3. Select and justify the correct management: octreotide (a somatostatin analog) suppresses vasoactive peptide secretion for symptom control, surgical resection is the only cure, and peptide receptor radionuclide therapy (PRRT) is used for unresectable metastatic disease.

Can you avoid these mistakes?

A 52-year-old man with known small intestinal carcinoid tumor has flushing and diarrhea but no hepatic metastases on imaging. His primary tumor drains via the portal vein. Why does he NOT have carcinoid syndrome, and what finding would change that?
A patient with carcinoid syndrome develops a rough, hyperpigmented rash on sun-exposed skin and confusion. Labs show low niacin levels. What is the mechanistic link between her carcinoid tumor and this presentation — and why is 'too much serotonin' an incomplete explanation?
You order urine 5-HIAA and serum chromogranin A on a patient suspected of having a neuroendocrine tumor. The 5-HIAA is normal but chromogranin A is markedly elevated. What does this pattern tell you, and what tumor type should you consider?
A patient with metastatic carcinoid syndrome is started on octreotide. Her attending explains that octreotide 'blocks serotonin.' Is that accurate? Describe the actual mechanism and explain how it reduces her flushing and diarrhea.

Related topics

Hypothalamic-Pituitary-Adrenal (HPA) Axis Hypothalamic-Pituitary-Thyroid (HPT) Axis Hypothalamic-Pituitary-Gonadal (HPG) Axis Hormone Signaling (Peptide vs Steroid)

See how your Anki deck covers this topic.

Upload your deck for a free audit →